« Back
Home /
Ciprofloxacin (monohydrochloride)

Ciprofloxacin (monohydrochloride)

Item no.	HY-B0356A-10mM
Manufacturer	MedChem Express
CASRN	93107-08-5
Amount	10mM*1 mL
Quantity options	10mM*1 mL 1 g 500 mg 5 g
Category	Oncology Food Safety Antibiotics Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Type	Inhibitors
Specific against	other
Purity	99.90
Citations	ACS Appl Polym Mater. 2023 Aug 29.<br/>bioRxiv. 2024 Jan 18.<br/>Adv Sci (Weinh). 2020 Jul 21;7(17):2001374.<br/>Anal Chim Acta. 15 June 2022, 340082.<br/>Animal Diseases. 02 November 2021.<br/>Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702.<br/>Arab J Chem. 2024 May, 17, 5, 105745.<br/>bioRxiv. 2024 May 10.<br/>Chemosphere. 2019 Jun;225:378-387. <br/>EBioMedicine. 2022 Apr;78:103943.<br/>Front Microbiol. 2022 Feb 16;12:773664.<br/>Genome Biol. 2023 Apr 30;24(1):98.<br/>Int J Antimicrob Agents. 2018 Aug;52(2):269-271.<br/>iScience. 2023 Oct 5.<br/>J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858.<br/>Microb Pathog. 2024 Apr 27:106666.<br/>Microbiol Spectr. 2022 Apr 25:e0251821.<br/>Microbiol Spectr. 2022 Jan 12;e0099121.<br/>Molecules. 2023 Jun 8, 28(12), 4628.<br/>Patent. US20200101105A1.<br/>Research Square Preprint. 2020 Jun.<br/>Vet Microbiol. 2024 May, 292, 110046.<br/>Water Res. 2023 May 21, 120110.<br/>Animal Diseases. 02 November 2021.<br/>bioRxiv. 2024 Feb 9.<br/>Nat Commun. 2022 Mar 2;13(1):1116.<br/>[1]Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63.<br/>[2]Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16.<br/>[3]Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.<br/>[4]LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804.
Smiles	[H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Bay-09867 (monohydrochloride)
Available
Product Description	Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].
StorageTemperature	4°C (Powder, sealed storage, away from moisture and light)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
MolecularWeight	367.80
Clinical Information	Launched
Manufacturers Research Area	Infection; Cancer
Solubility	DMSO : 5 mg/mL (ultrasonic)\|H2O : 12.5 mg/mL (ultrasonic)
Target	Antibiotic; Apoptosis; Bacterial; Mitochondrial Metabolism; Reactive Oxygen Species; Topoisomerase
Manufacturers Target	Antibiotic; Apoptosis; Bacterial; Mitochondrial Metabolism; Reactive Oxygen Species; Topoisomerase
Isoform	Quinolone
Manufacturers Pathway	Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10mM*1 mL

available

Request delivery time